Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,497 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07409987 | TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy | completed | N/A | 140 | Cumhuriyet UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | recruiting | Phase 3 | 2,130 | AstraZenecaINDUSTRY | 24 | Sep 9, 2026 |
| NCT07794904 | Effectiveness of a Tele-Rehabilitation-Based Exercise and Self-Lymphatic Drainage Program Supported by Self-Management for Breast Cancer-Related Lymphedema | active not recruiting | N/A | 64 | Istanbul UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07809386 | The Effect of Gamified Sleep Hygiene Education on Sleep Quality and Fatigue Levels in Chemotherapy Patients | not yet recruiting | N/A | 56 | Lokman Hekim UniversityOTHER_GOV | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer(SUNRAY-01) | recruiting | Phase 3 | 1,264 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 8, 2026 | clinicaltrials |
| NCT07005128 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)(DeLLphi-312) | active not recruiting | Phase 3 | 350 | AmgenINDUSTRY | 26 | Sep 8, 2026 | clinicaltrials |
| NCT07509151 | Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)(SOUNDTRACK-C1) | recruiting | Phase 3 | 420 | AstraZenecaINDUSTRY | 5 | Sep 8, 2026 | clinicaltrials |
| NCT07806539 | Hemodynamic Monitoring-Guided Goal-Directed Fluid Therapy in Robotic Radical Prostatectomy | completed | — | 48 | Antalya Training and Research HospitalOTHER_GOV | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | recruiting | Phase 2 / Phase 3 | 1,800 | St. Anna KinderkrebsforschungOTHER | 31 | Sep 4, 2026 | clinicaltrials |
| NCT04680052 | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.(InMIND) | active not recruiting | Phase 3 | 654 | Incyte CorporationINDUSTRY | 28 | Sep 4, 2026 | clinicaltrials |
| NCT04821622 | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | active not recruiting | Phase 3 | 599 | PfizerINDUSTRY | 27 | Sep 4, 2026 | clinicaltrials |
| NCT07169851 | A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | recruiting | Phase 2 | 204 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 4, 2026 | clinicaltrials |
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations(TROPION-Lung17) | recruiting | Phase 3 | 400 | AstraZenecaINDUSTRY | 21 | Sep 4, 2026 | clinicaltrials |
| NCT07368998 | To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer(optINAVO) | recruiting | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT07724678 | Comparison of Combined (Superficial and Deep) and Isolated Deep Serratus Anterior Plane Blocks After Breast Surgery | completed | — | 76 | SBU Ankara Egitim ve Arastirma HastanesiOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07778875 | Self-Reported Colorectal Cancer Screening Uptake(CRC-HBM) | completed | N/A | 176 | Bartın UnıversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST) | active not recruiting | Phase 2 / Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT03459534 | A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | recruiting | Phase 3 | 173 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 4 | Sep 3, 2026 | clinicaltrials |
| NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | active not recruiting | Phase 3 | 257 | PfizerINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy(Astefania) | active not recruiting | Phase 3 | 1,188 | Hoffmann-La RocheINDUSTRY | 32 | Sep 3, 2026 | clinicaltrials |
| NCT05568095 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body(STAR-221) | completed | Phase 3 | 1,040 | Arcus Biosciences, Inc.INDUSTRY | 29 | Sep 3, 2026 | clinicaltrials |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)(OMAHA-003) | recruiting | Phase 3 | 1,310 | Merck Sharp & Dohme LLCINDUSTRY | 36 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | recruiting | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 3, 2026 | clinicaltrials |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma(ARTEMIDE-HCC01) | recruiting | Phase 3 | 1,220 | AstraZenecaINDUSTRY | 20 | Sep 3, 2026 | clinicaltrials |
| NCT07287150 | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer(InavoPC) | recruiting | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07413939 | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive(BREnnA) | recruiting | Phase 2 / Phase 3 | 650 | Hoffmann-La RocheINDUSTRY | 25 | Sep 3, 2026 | clinicaltrials |
| NCT07650773 | CHARM Hepatocellular Carcinoma MEA Study | recruiting | — | 4,000 | AstraZenecaINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT07697729 | Relationship Between Metrnl Expression, IL-1β, and TNF-α in Patients With Peri-Implantitis | completed | — | 68 | Ataturk UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802197 | Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer(PRELUDE) | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07803159 | Frailty, Immunonutrition, Surgery Type, and Biologic Recovery in Elderly Gastric Cancer | not yet recruiting | — | 328 | Kocaeli City HospitalOTHER_GOV | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT05405166 | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM(IRAKLIA) | active not recruiting | Phase 3 | 531 | SanofiINDUSTRY | 21 | Sep 2, 2026 | clinicaltrials |
| NCT05879822 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | active not recruiting | Phase 2 | 73 | Incyte CorporationINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07252739 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | recruiting | Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT07656311 | Mean Platelet Volume (MPV) as an Early Predictor of Mortality in Intensive Care Patients With Cancer(MPV-CICU) | completed | — | 425 | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03547973 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread(TROPHY U-01) | active not recruiting | Phase 2 | 502 | Gilead SciencesINDUSTRY | 9 | Sep 1, 2026 | clinicaltrials |
| NCT05508867 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | completed | Phase 2 | 203 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 1, 2026 | clinicaltrials |
| NCT05909904 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 160 | BeiGeneINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT05967689 | A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.(REZILIENT2) | recruiting | Phase 2 | 220 | Taiho Oncology, Inc.INDUSTRY | 12 | Sep 1, 2026 | clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT06799247 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | active not recruiting | Phase 3 | 128 | Cartesian TherapeuticsINDUSTRY | 8 | Sep 1, 2026 | clinicaltrials |
| NCT07579650 | Serratus Posterior Superior Intercostal Plane Block for Postoperative Analgesia in Mastectomy | recruiting | N/A | 50 | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07798492 | Effects of Supervised Aerobic Exercise on Biomarkers, Physical Function, and Quality of Life in Breast Cancer Survivors | active not recruiting | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
Data updated 21 days agoSource updated unknownsource: clinicaltrials